KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Vertex Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $4.64 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $4.64 for Q4 2025, up 31.44% from a year ago — trailing twelve months through Dec 2025 was $15.32 (up 805.99% YoY), and the annual figure for FY2025 was $15.32, up 836.54%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $4.64 at Vertex Pharmaceuticals, up from $4.2 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for VRTX hit a ceiling of $4.64 in Q4 2025 and a floor of -$13.92 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $3.4 (2021), compared with a mean of $2.44.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 1103.85% in 2022 and later crashed 495.45% in 2024.
  • Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $2.98 in 2021, then grew by 5.37% to $3.14 in 2022, then increased by 18.15% to $3.71 in 2023, then fell by 4.85% to $3.53 in 2024, then skyrocketed by 31.44% to $4.64 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $4.64 (Q4 2025), $4.2 (Q3 2025), and $3.99 (Q2 2025) per Business Quant data.